Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
3.195
-0.185 (-5.47%)
Mar 31, 2025, 10:59 AM EDT - Market open

Corvus Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
8.166.87.519.2811.93
Upgrade
Research & Development
19.3916.5324.4729.1231.83
Upgrade
Operating Expenses
27.5523.3331.9838.443.76
Upgrade
Operating Income
-27.55-23.33-31.98-38.4-43.76
Upgrade
Interest & Investment Income
1.821.580.65-0.54
Upgrade
Earnings From Equity Investments
-3.2-5.28-10.01-4.83-0.23
Upgrade
Other Non Operating Income (Expenses)
-33.38---0.02-
Upgrade
EBT Excluding Unusual Items
-62.3-27.03-41.33-43.24-43.45
Upgrade
Gain (Loss) on Sale of Assets
0.01-0.02-37.46
Upgrade
Pretax Income
-62.29-27.03-41.31-43.24-6
Upgrade
Net Income
-62.29-27.03-41.31-43.24-6
Upgrade
Net Income to Common
-62.29-27.03-41.31-43.24-6
Upgrade
Shares Outstanding (Basic)
6148474229
Upgrade
Shares Outstanding (Diluted)
6148474229
Upgrade
Shares Change (YoY)
26.99%3.16%11.23%41.98%0.44%
Upgrade
EPS (Basic)
-1.02-0.56-0.89-1.03-0.20
Upgrade
EPS (Diluted)
-1.02-0.56-0.89-1.03-0.20
Upgrade
Free Cash Flow
-25.42-23.97-27.29-36.72-34.85
Upgrade
Free Cash Flow Per Share
-0.42-0.50-0.59-0.88-1.18
Upgrade
EBITDA
-27.46-23.18-31.61-37.94-43.13
Upgrade
D&A For EBITDA
0.090.150.370.460.63
Upgrade
EBIT
-27.55-23.33-31.98-38.4-43.76
Upgrade
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q